» Articles » PMID: 33704908

Theragnostic Chromosomal Rearrangements in Treatment-naive Pancreatic Ductal Adenocarcinomas Obtained Via Endoscopic Ultrasound

Abstract

A crucial mutational mechanism in malignancy is structural variation, in which chromosomal rearrangements alter gene functions that drive cancer progression. Herein, the presence and pattern of structural variations were investigated in twelve prospectively acquired treatment-naïve pancreatic cancers specimens obtained via endoscopic ultrasound (EUS). In many patients, this diagnostic biopsy procedure and specimen is the only opportunity to identify somatic clinically relevant actionable alterations that may impact their care and outcome. Specialized mate pair sequencing (MPseq) provided genome-wide structural variance analysis (SVA) with a view to identifying prognostic markers and possible therapeutic targets. MPseq was successfully performed on all specimens, identifying highly rearranged genomes with complete SVA on all specimens with > 20% tumour content. SVA identified chimeric fusion proteins and potentially immunogenic readthrough transcripts, change of function truncations, gains and losses of key genes linked to tumour progression. Complex localized rearrangements, termed chromoanagenesis, with broad pattern heterogeneity were observed in 10 (83%) specimens, impacting multiple genes with diverse cellular functions that could influence theragnostic evaluation and responsiveness to immunotherapy regimens. This study indicates that genome-wide MPseq can be successfully performed on very limited clinically EUS obtained specimens for chromosomal rearrangement detection and potential theragnostic targets.

Citing Articles

Adequacy of EUS-guided fine-needle aspiration and fine-needle biopsy for next-generation sequencing in pancreatic malignancies: A systematic review and meta-analysis.

Pan Y, Ran T, Zhang X, Qin X, Zhang Y, Zhou C Endosc Ultrasound. 2025; 13(6):366-375.

PMID: 39802109 PMC: 11723693. DOI: 10.1097/eus.0000000000000097.


Theragnostic chromosomal rearrangements in treatment-naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound.

Murphy S, Levy M, Smadbeck J, Karagouga G, McCune A, Harris F J Cell Mol Med. 2021; 25(8):4110-4123.

PMID: 33704908 PMC: 8051743. DOI: 10.1111/jcmm.16381.

References
1.
Pishvaian M, Blais E, Brody J, Lyons E, DeArbeloa P, Hendifar A . Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020; 21(4):508-518. PMC: 7453743. DOI: 10.1016/S1470-2045(20)30074-7. View

2.
Hartley C, Mahajan A, Selvaggi S, Rehrauer W . FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples. Cancer Cytopathol. 2017; 125(11):838-847. DOI: 10.1002/cncy.21935. View

3.
Voller D, Linck L, Bruckmann A, Hauptmann J, Deutzmann R, Meister G . Argonaute Family Protein Expression in Normal Tissue and Cancer Entities. PLoS One. 2016; 11(8):e0161165. PMC: 4982624. DOI: 10.1371/journal.pone.0161165. View

4.
Yao W, Maitra A, Ying H . Recent insights into the biology of pancreatic cancer. EBioMedicine. 2020; 53:102655. PMC: 7118569. DOI: 10.1016/j.ebiom.2020.102655. View

5.
Fujioka S, Sclabas G, Schmidt C, Frederick W, Dong Q, Abbruzzese J . Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res. 2003; 9(1):346-54. View